Exzidieren oder nicht: Auswirkung von MelaFind auf Biopsie-Entscheidungen atypischer Läsionen bei deutschen Dermatologen

Translated title of the contribution: To excise or not: Impact of MelaFind on German dermatologists' decisions to biopsy atypical lesions

Axel Hauschild, Suephy C. Chen, Michael Weichenthal, Andreas Blum, Hadley C. King, Jeff Goldsmith, Daniel O Scharfstein, Dina Gutkowicz-Krusin

Research output: Contribution to journalArticle

Abstract

Objectives: To determine the biopsy sensitivity to melanoma of dermatologists in Germany and the impact of MelaFind® on their decisions to biopsy melanomas. Design Randomized two-armed online reader study presenting case information, clinical/dermatoscopic images of pigmented skin lesions and MelaFind results (Arm 2). Methods: Each participant was asked to review 130 pigmented skin lesions. Biopsy decisions of dermatologists without MelaFind versus MelaFind and dermatologists without MelaFind versus dermatologists with MelaFind were compared. Results: Dermatologists without MelaFind had average sensitivity to melanoma of 69.5 % and average specificity of 55.9 %. MelaFind had greater sensitivity than dermatologists alone (96.9 % vs. 69.5 %, one-sided p <0.00001) and lower specificity (9.2 % vs. 55.9 %, one-sided p <0.00001). Dermatologists with MelaFind had higher sensitivity than those without MelaFind (78 % vs. 69.5 %, one-sided p <0.00001) and a lower specificity (45.8 % vs. 55.9 %, one-sided p <0.00001). The number of dermatologists detecting over 90 % of melanomas increased from 3 of 101 without MelaFind to 22 of 101 with MelaFind (p = 0.00006) while specificity remained relatively equivalent (23 % vs. 21 %, p = 0.99). Conclusions: The MelaFind information, when incorporated into the final biopsy decision, can improve biopsy sensitivity with modest effect on biopsy specificity.

Original languageGerman
Pages (from-to)606-616
Number of pages11
JournalJDDG - Journal of the German Society of Dermatology
Volume12
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Biopsy
Melanoma
Skin
Dermatologists
Germany

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Exzidieren oder nicht : Auswirkung von MelaFind auf Biopsie-Entscheidungen atypischer Läsionen bei deutschen Dermatologen. / Hauschild, Axel; Chen, Suephy C.; Weichenthal, Michael; Blum, Andreas; King, Hadley C.; Goldsmith, Jeff; Scharfstein, Daniel O; Gutkowicz-Krusin, Dina.

In: JDDG - Journal of the German Society of Dermatology, Vol. 12, No. 7, 2014, p. 606-616.

Research output: Contribution to journalArticle

Hauschild, Axel ; Chen, Suephy C. ; Weichenthal, Michael ; Blum, Andreas ; King, Hadley C. ; Goldsmith, Jeff ; Scharfstein, Daniel O ; Gutkowicz-Krusin, Dina. / Exzidieren oder nicht : Auswirkung von MelaFind auf Biopsie-Entscheidungen atypischer Läsionen bei deutschen Dermatologen. In: JDDG - Journal of the German Society of Dermatology. 2014 ; Vol. 12, No. 7. pp. 606-616.
@article{d98b0ca8fea14927b5a885e45bae642f,
title = "Exzidieren oder nicht: Auswirkung von MelaFind auf Biopsie-Entscheidungen atypischer L{\"a}sionen bei deutschen Dermatologen",
abstract = "Objectives: To determine the biopsy sensitivity to melanoma of dermatologists in Germany and the impact of MelaFind{\circledR} on their decisions to biopsy melanomas. Design Randomized two-armed online reader study presenting case information, clinical/dermatoscopic images of pigmented skin lesions and MelaFind results (Arm 2). Methods: Each participant was asked to review 130 pigmented skin lesions. Biopsy decisions of dermatologists without MelaFind versus MelaFind and dermatologists without MelaFind versus dermatologists with MelaFind were compared. Results: Dermatologists without MelaFind had average sensitivity to melanoma of 69.5 {\%} and average specificity of 55.9 {\%}. MelaFind had greater sensitivity than dermatologists alone (96.9 {\%} vs. 69.5 {\%}, one-sided p <0.00001) and lower specificity (9.2 {\%} vs. 55.9 {\%}, one-sided p <0.00001). Dermatologists with MelaFind had higher sensitivity than those without MelaFind (78 {\%} vs. 69.5 {\%}, one-sided p <0.00001) and a lower specificity (45.8 {\%} vs. 55.9 {\%}, one-sided p <0.00001). The number of dermatologists detecting over 90 {\%} of melanomas increased from 3 of 101 without MelaFind to 22 of 101 with MelaFind (p = 0.00006) while specificity remained relatively equivalent (23 {\%} vs. 21 {\%}, p = 0.99). Conclusions: The MelaFind information, when incorporated into the final biopsy decision, can improve biopsy sensitivity with modest effect on biopsy specificity.",
author = "Axel Hauschild and Chen, {Suephy C.} and Michael Weichenthal and Andreas Blum and King, {Hadley C.} and Jeff Goldsmith and Scharfstein, {Daniel O} and Dina Gutkowicz-Krusin",
year = "2014",
doi = "10.1111/ddg.12362",
language = "German",
volume = "12",
pages = "606--616",
journal = "JDDG - Journal of the German Society of Dermatology",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Exzidieren oder nicht

T2 - Auswirkung von MelaFind auf Biopsie-Entscheidungen atypischer Läsionen bei deutschen Dermatologen

AU - Hauschild, Axel

AU - Chen, Suephy C.

AU - Weichenthal, Michael

AU - Blum, Andreas

AU - King, Hadley C.

AU - Goldsmith, Jeff

AU - Scharfstein, Daniel O

AU - Gutkowicz-Krusin, Dina

PY - 2014

Y1 - 2014

N2 - Objectives: To determine the biopsy sensitivity to melanoma of dermatologists in Germany and the impact of MelaFind® on their decisions to biopsy melanomas. Design Randomized two-armed online reader study presenting case information, clinical/dermatoscopic images of pigmented skin lesions and MelaFind results (Arm 2). Methods: Each participant was asked to review 130 pigmented skin lesions. Biopsy decisions of dermatologists without MelaFind versus MelaFind and dermatologists without MelaFind versus dermatologists with MelaFind were compared. Results: Dermatologists without MelaFind had average sensitivity to melanoma of 69.5 % and average specificity of 55.9 %. MelaFind had greater sensitivity than dermatologists alone (96.9 % vs. 69.5 %, one-sided p <0.00001) and lower specificity (9.2 % vs. 55.9 %, one-sided p <0.00001). Dermatologists with MelaFind had higher sensitivity than those without MelaFind (78 % vs. 69.5 %, one-sided p <0.00001) and a lower specificity (45.8 % vs. 55.9 %, one-sided p <0.00001). The number of dermatologists detecting over 90 % of melanomas increased from 3 of 101 without MelaFind to 22 of 101 with MelaFind (p = 0.00006) while specificity remained relatively equivalent (23 % vs. 21 %, p = 0.99). Conclusions: The MelaFind information, when incorporated into the final biopsy decision, can improve biopsy sensitivity with modest effect on biopsy specificity.

AB - Objectives: To determine the biopsy sensitivity to melanoma of dermatologists in Germany and the impact of MelaFind® on their decisions to biopsy melanomas. Design Randomized two-armed online reader study presenting case information, clinical/dermatoscopic images of pigmented skin lesions and MelaFind results (Arm 2). Methods: Each participant was asked to review 130 pigmented skin lesions. Biopsy decisions of dermatologists without MelaFind versus MelaFind and dermatologists without MelaFind versus dermatologists with MelaFind were compared. Results: Dermatologists without MelaFind had average sensitivity to melanoma of 69.5 % and average specificity of 55.9 %. MelaFind had greater sensitivity than dermatologists alone (96.9 % vs. 69.5 %, one-sided p <0.00001) and lower specificity (9.2 % vs. 55.9 %, one-sided p <0.00001). Dermatologists with MelaFind had higher sensitivity than those without MelaFind (78 % vs. 69.5 %, one-sided p <0.00001) and a lower specificity (45.8 % vs. 55.9 %, one-sided p <0.00001). The number of dermatologists detecting over 90 % of melanomas increased from 3 of 101 without MelaFind to 22 of 101 with MelaFind (p = 0.00006) while specificity remained relatively equivalent (23 % vs. 21 %, p = 0.99). Conclusions: The MelaFind information, when incorporated into the final biopsy decision, can improve biopsy sensitivity with modest effect on biopsy specificity.

UR - http://www.scopus.com/inward/record.url?scp=84903979245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903979245&partnerID=8YFLogxK

U2 - 10.1111/ddg.12362

DO - 10.1111/ddg.12362

M3 - Article

C2 - 24944011

AN - SCOPUS:84903979245

VL - 12

SP - 606

EP - 616

JO - JDDG - Journal of the German Society of Dermatology

JF - JDDG - Journal of the German Society of Dermatology

SN - 1610-0379

IS - 7

ER -